Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06850571 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Aflibercept and Bevacizumab for Diabetic Maculopathies

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Sep 1, 2025 to Dec 1, 2025v4
  2. Primary and study completion dates: Jul 1, 2025 to Sep 1, 2025v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include: * Functional changes: The visual outcomes achieved by testing visual acuity * Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).
Trial Details
NCT Number NCT06850571
Lead Sponsor Al-Mustansiriyah University
Collaborators: Baghdad Medical City
Conditions
(from sponsor)		 Diabetic Maculopathy
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov